Chemically diverse antagonists inhibit human TRPV1 through ligand-specific interaction networks

Pain is a complex signal, a warning system that tells the body when something is hot, sharp, or damaging. For decades, scientists have looked to a specific protein in our nerve cells, called TRPV1, to understand how this warning system works and how to turn it off when pain becomes chronic. This protein acts like a gatekeeper, opening a channel to let electrical signals flow when it detects heat or certain chemicals, such as the capsaicin found in chili peppers. While drugs that block this gate could offer powerful relief without the risks of addiction associated with opioids, previous attempts have stumbled. The main problem has been that these blockers often shut down the body's natural ability to sense temperature, causing dangerous fevers or a loss of heat sensation. To design better medicines, researchers needed to see exactly how different drugs lock this gate from the inside, but until now, they lacked clear pictures of the human version of this protein holding these specific blockers.

A team of researchers has now taken a high-resolution look at the human TRPV1 protein, capturing images of it bound to several different drug candidates, including some that have been tested in people. Using a powerful imaging technique that allows them to see individual atoms, the scientists solved the structures of the protein with four distinct antagonists—molecules designed to stop the channel from opening. They also studied how the protein behaves when it is empty and when it is held by a modified version of capsaicin that acts as a blocker instead of an activator. By comparing these snapshots, the team discovered that the protein's internal pocket, where the drugs bind, is far more flexible than previously thought. It can stretch and reshape itself to hold very different chemical shapes, yet despite these different ways of binding, every single drug forces the channel into the same closed, inactive state.

The study began by examining a simple change: replacing a single hydrogen atom in a capsaicin molecule with a larger iodine atom. This tiny substitution, which adds just one heavy atom to the structure, flips the molecule from a potent pain inducer into a potent pain blocker. The researchers found that this iodine atom acts like a physical wedge inside the protein's binding pocket. It pushes against a specific part of the channel's internal machinery, preventing the gate from opening even though the molecule is sitting in the same spot as the original capsaicin. This revealed a critical mechanism: to stop the channel, a drug does not need to pull the gate shut from the outside; it can simply jam the internal gears so they cannot turn.

The team then looked at three other drugs that are chemically very different from capsaicin and from each other. One of these, a drug called Asivatrep, was found to bind in a way that leaves a small gap in the pocket, which is then filled by a lipid molecule—a fat-like component of the cell membrane. This suggests that the drug and the cell's own natural fats can work together to lock the channel. Another drug, Mavatrep, fits into a much tighter, more compact space, while a third, JNJ-17203212, binds without touching a key amino acid that most other drugs rely on. Despite these wildly different ways of sitting in the pocket, all three drugs successfully force the channel into a closed position. The researchers confirmed these structural findings by testing the drugs in living cells, showing that they all effectively stop the channel from opening, even though they use different molecular strategies to get there.

Perhaps the most surprising discovery was that the rules scientists thought were necessary to block the channel were not actually required. For years, it was believed that a drug had to break a specific chemical bridge inside the protein to stop it from working. However, the new images showed that one of the drugs, Mavatrep, keeps this bridge intact while still successfully shutting the gate. Similarly, another drug, JNJ-17203212, manages to block the channel without touching a specific amino acid that was thought to be essential for binding. This means the protein has multiple ways to be turned off, and the path to a closed state is not a single, rigid track but a flexible landscape that different drugs can navigate in their own unique ways.

The researchers also tested how changing specific parts of the protein affected the drugs. When they altered the amino acids that the drugs were seen touching in the images, the drugs lost their ability to bind, but only for the specific drugs that were touching those spots. This confirmed that the different chemical shapes of the drugs rely on different sets of contacts to hold on. The study also highlighted that the human version of this protein behaves differently than the versions found in rats, which explains why some drugs that worked well in animals failed in human trials. By focusing on the human structure, the team provided a more accurate map for future drug design.

These findings suggest that the path to better pain relief lies in exploiting this flexibility. Because the protein can accommodate many different shapes and still achieve the same result—closing the gate—scientists can now design drugs that target the specific interactions needed to block pain without triggering the side effects related to temperature sensing. The work shows that high potency does not require a single, perfect fit, but rather the ability to find a stable, closed state through various routes. By understanding these diverse ways the human TRPV1 channel can be locked, researchers can now aim to create the next generation of painkillers that offer relief without the dangerous loss of temperature control that has plagued previous attempts.